Mechanisms of broad-spectrum antiemetic efficacy of cannabinoids against chemotherapy-induced acute and delayed vomiting

Pharmaceuticals

Volumn 3, Issue 9, 2010, Pages 2930-2955

  Darmani, Nissar A ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Acute; Antiemetics; Cannabinoids; Chemotherapy; Delayed; Emesis; Endocannabinoids

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 4 (PIPERID 1 YLACETAMIDO)BENZOIC ACID ETHYL ESTER; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CHLORPROMAZINE; CISPLATIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXAMETHASONE; DEXANABINOL; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ENDOCANNABINOID; HALOPERIDOL; LEVONANTRADOL; NABILONE; ONDANSETRON; PROCHLORPERAZINE; RESINIFERATOXIN; RIMONABANT; TETRAHYDROCANNABINOLIC ACID; TROPISETRON; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANTIEMETIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DYSPNEA; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE INNERVATION; LOW DRUG DOSE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PANIC; PERIPHERAL NERVOUS SYSTEM FUNCTION; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SENSORY NERVE; SOLITARY TRACT NUCLEUS; TISSUE LEVEL; VAGUS NERVE DORSAL NUCLEUS; VAGUS REFLEX; VOMITING;

EID: 77957280149     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3092930     Document Type: Review

References (133)

1. Darmani, N.A.; Ray, A.P. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem. Rev. 2009, 109, 3158-3199.
2. 9-tetrahydrocannabinol and synthetic cannabinoids. in chemotherapy-induced nausea and vomiting. In Biology of Marijuana: From Gene to Behavior, Onaivi, E.S., Ed.; Taylor and Francis Books Ltd.: London, UK, 2002; pp. 356-389.
3. Slatkin, N.E. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J. Support Oncol. 2007, 5, 1-9.
4. Darmani, N.A. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001, 24, 198-203.
5. Ray, A.P.; Griggs, L.; Darmani, N.A. Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav. Brain Res. 2009, 196, 30-36.
6. Van Sickle, M.D.; Oland, L.D.; Ho, W.; Hillard, C.J.; Mackie, K.; Davison, J.S.; Sharkey, K.A. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001, 121, 767-774.
7. Van Sickle, M.D.; Oland, L.D.; Mackie, K.; Davison, J.S.; Sharkey, K.A. Delta9- tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am. J. Physio. Gastrointest Liver Physiol. 2003, 285, G566-G576.
8. Di Marzo, V. CB(1) receptor antagonism: biological basis for metabolic effects. Drug Discov. Today 2008, (23-24), 1026-1041.
9. Sharkey, K. A.; Cristino, L.; Oland, L. D.; Van Sickle, M. D.; Starowicz, K.; Pittman, Q. J.; Guglielmotti, V.; Davison, J. S.; Di Marzo, V. Arvanil, anandamide and N-arachidonoyldopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur. J. Neurosci. 2007, 25, 2773-2782.
10. Parker, L.A.; Limebeer, C.L.; Rock, E.M.; Litt, D.L.; Kwaitkowska, M.; Piomelli, D. The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol. Behav. 2009, 97, 121-124.
11. Darmani, N. A. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannabinoids. J. Pharmacol. Exp. Ther. 2002, 300, 34-42.
12. Andrews, P.L.R.; Rudd, J.A. The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. J. Exp. Pharmacol. 2004, 164, 359-340.
13. Endo, T.; Minami, M.; Hirafuji, M.; Ogawa, T.; Akita, K.; Nemoto, M.; Saito, H.; Yoshioka, M.; Parvez, S.H. Neurochemistry and neuropharmacology of emesis - the role of serotonin. Toxicology 2000, 153, 189-201.
14. Koch, K. L. Approach to the patient with nausea and vomiting. In Textbook of Gastroenterology; Yamada, T., Ed; Lippincott: Philadelphia, PA, USA, 1995; pp. 83-388.
15. Tanihata, S.; Oda, S.; Kakuta, S.; Uchiyama, T. Antiemetic effect of a tachykinin NK1 receptor antagonist GR205171 on cisplatin-induced early and delayed emesis in the pigeon. Eur. J. Pharmacol. 2003, 461, 197-206.
16. Darmani, N. A.; Crim, J. L.; Janoyan, J. J.; Abad, J.; Ramirez, J. A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res. 2009, 1248, 40-58.
17. Jordan, K.; Schmoll, H. J.; Aapro, M. S. Comparative activity of antiemetic drugs. Crit. Rev. Oncol. Hematol. 2007, 61, 162-175.
18. Rudd, J. A.; Jordan, C. C.; Naylor, R. J. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br. J. Pharmacol. 1996, 119, 931-936.
19. Sam, T. S.; Cheng, J. T.; Johnston, K. D.; Kan, K. K.; Ngan, M. P.; Rudd, J. A.; Wai, M. K.; Yeung, J. H. Action of 5-HT3 receptor antagonists and dexamethasone to modify cisplatininduced emesis in Suncus murinus (house musk shrew). Eur. J. Pharmacol. 2003, 472, 135-145.
20. Hesketh, P. J.; Van Belle, S.; Aapro, M.; Tattersall, F. D.; Naylor, R. J.; Hargreaves, R.; Carides, A. D.; Evans, J. K.; Horgan, K. J. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer 2003, 39, 1074-1080.
21. Milano, S.; Blower, P.; Romain, D.; Grelot, L. The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. J. Pharmacol. Exp. Ther. 1995, 274, 951-961.
22. Rudd, J. A.; Tse, J. Y. H.; Wai, M. K. Cisplatin-induced emesis in the cat: effect of granisetron and dexamethasone. Eur. J. Pharmacol. 2000, 391, 145-150.
23. Minami, M.; Endo, T.; Hirafuji, M.; Hamaue, N.; Liu, Y.; Hiroshige, T.; Nemoto, M.; Saito, H.; Yoshioka, M. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol. Ther. 2003, 99, 149-165.
24. Hansen, M. B, Witte, A. B. The role of serotonin in intestinal luminal sensing and secretion. Acta Physiol. (Oxf) 2008, 193, 311-323.
25. Sjolund, K.; Sanden, G.; Hakanson, R.; Sundler, F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 1983, 85, 1120-1130.
26. Fukui, H.; Yamamoto, M.; Ando, T.; Sasaki, S.; Sato, S. Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysis. Neuropharmacology 1993, 32, 959-968.
27. Gershon, M. D. 5-HT (serotonin) physiology and related drugs. Curr. Opin. Gastroenterol. 2000, 16, 113-120.
28. Li, Z. S.; Pham, T. D.; Tamir, H.; Chen, J. J.; Gershon, M. D. Enteric dopaminergic neurons: definition, developmental lineage, and effects of extrinsic denervation. J. Neurosci. 2004, 24, 1330-1339.
29. Holzer, P.; Holzer-Petsche, U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol. Ther. 1997, 73, 173-217.
30. Minami, M.; Endo, T.; Yokota, H.; Ogawa, T.; Nemoto, M.; Hamaue, N.; Hirafuji, M.; Yoshioka, M.; Nagahisa, A.; Andrews, P. L. Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur. J. Pharmacol. 2001, 428, 215-220.
31. Zhu, J. X.; Zhu, X. Y.; Owyang, C.; Li, Y. Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. J. Physiol. 2001, 530, 431-442.
32. Cordoba-Rodriguez, R.; Moore, K. A.; Kao, J. P.; Weinreich, D. Calcium regulation of a slow post-spike hyperpolarization in vagal afferent neurons. Proc. Natl. Acad. Sci. USA 1999, 96, 7650-7657.
33. Munoz, N. M.; Shioya, T.; Murphy, T. M.; Primack, S.; Dame, C.; Sands, M. F.; Leff, A. R. Potentiation of vagal contractile response by thromboxane mimetic U-46619. J. App. Physiol. 1986, 61, 1173-1179.
34. Rudd, J. A.; Qian, Y.; Tsui, K. K.; Jones, R. L. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br. J. Pharmacol. 2000, 129, 782-790.
35. + currents involves activation of both EP2 and EP4 receptors in neonatal rat nodose ganglion neurons. Br. J. Pharmacol. 2005, 145, 503-513.
36. Nakamura, K.; Kaneko, T.; Yamashita, Y.; Hasegawa, H.; Katoh, H.; Negishi, M. Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous system. J. Comp. Neurol. 2000, 421, 543-569.
37. Kummer, W.; Bachmann, S.; Neuhuber, W. L.; Hanze, J.; Lang, R. E. Tyrosine-hydroxylasecontaining vagal afferent neurons in the rat nodose ganglion are independent from neuropeptide-Ycontaining populations and project to esophagus and stomach. Cell Tissue Res. 1993, 271, 135-144.
38. Lawrence, A. J.; Krstew, E.; Jarrott, B. Functional dopamine D2 receptors on rat vagal afferent neurons. Br. J. Pharmacol. 1995, 114, 1329-1334.
39. Minami, M.; Nemoto, M.; Endo, T.; Hamaue, N.; Kohno, Y. Effects of talipexole on emesisrelated changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Res. Commun. Mol. Pathol. Pharmacol. 1997, 95, 67-82.
40. Darmani, N. A.; Wang, Y.; Abad, J.; Ray, A. P.; Thrush, G. R.; Ramirez, J. Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists. Brain Res. 2008, 1214, 58-72.
41. Arluison, M.; Derer, P. Forebrain connections of the rat paraventricular thalamic nucleus as demonstrated using the carbocyanide dye DiI. Neurobiology (Bp) 1993, 1, 337-350.
42. Browning, K. N.; Travagli, R. A. Short-term receptor trafficking in the dorsal vagal complex: an overview. Auton. Neurosci.2006, 126-127, 2-8.
43. Hyde, T. M.; Knable, M. B.; Murray, A. M. Distribution of dopamine D1-D4 receptor subtypes in human dorsal vagal complex. Synapse 1996, 24, 224-232.
44. Ito, H.; Seki, M. Ascending projections from the area postrema and the nucleus of the solitary tract of Suncus murinus: anterograde tracing study using Phaseolus vulgaris leucoagglutinin. Okajimas Folia Anat. Jpn. 1998, 75, 9-31.
45. Koga, T.; Fukuda, H. Neurons in the nucleus of the solitary tract mediating inputs from emetic vagal afferents and the area postrema to the pattern generator for the emetic act in dog. Neurosci. Res. 1992, 14, 166-179.
46. McRitchie, D. A.; Töurk, I. Distribution of substance P-like immunoreactive neurons and terminals throughout the nucleus of the solitary tract in the human brainstem. J. Comp. Neurol. 1994, 343, 83-101.
47. Miller, A. D.; Nonaka, S.; Jakus, J. Brain areas essential or non-essential for emesis. Brain Res. 1994, 647, 255-264.
48. Ricardo, J. A.; Koh, E. T. Anatomical evidence of direct projections from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. Brain Res. 1978, 153, 1-26.
49. Travagli, R. A.; Hermann, G. E.; Browning, K. N.; Rogers, R. C. Brainstem circuits regulating gastric function. Ann. Rev. Physiol. 2006, 68, 279-305.
50. Onishi, T.; Mori, T.; Yanagihara, M.; Furukawa, N.; Fukuda, H. Similarities of the neuronal circuit for the induction of fictive vomiting between ferrets and dogs. Auton. Neurosci. 2007, 136, 20-30.
51. Hornby, P.J. Central neurocircuitry associated with emesis. Am. J. Med. 2001, 111 (Suppl. 8A), 106S-112S.
52. Hornby, P.J.; Abrahams, T.P. Central control of lower esophageal sphincter relaxation. Am. J. Med. 2000, 108, 90S-98S.
53. Urayama, Y.; Yamada, Y.; nakamura, E.; Koga, T.; Fukuda, H. Electrical and chemical stimulation of the nucleus raphe magnus inhibits induction of retching by afferent vagal fibers. Auton. Neurosci. 2010, 152, 35-40.
54. Partosoedarso, E.R.; Abrahams, T.P.; Scullion, R.T.; Moerschbaecher, J.M.; Hornby, P.J.Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J. Physiol. 2003, 550, 149-158.
55. Browning, K.N.; Travagli, R.A. Characterization of the in vitro effects of 5-hydroxytryptamine (5-HT) on identified neurones of the rat dorsal motor nucleus of the vagus (DMV). Br. J. Pharmacol. 1999, 128, 1307-1315.
56. Carpenter, D.O; Briggs, D.B.; Strominger, N. Behavioral and electrophysiological studies of peptide-induced emesis in dogs. Fed. Proc. 1984, 43, 2952-2954.
57. Di Marzo, V. Endocannabinoids: synthesis and degradation. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol. 2008, 160, 1-24.
58. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389-462.
59. Van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. J.; Di Marzo, V.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310, 329-332.
60. Chebolu, S.; Wang, Y.; Ray, A.P.; Darmani, N.A. Pranlukast prevents cysteinyl leukotrieneinduced emesis in the least shrew (Cryptotis parva). Eur. J. Pharmacol. 2010, 628, 195-201.
61. Izzo, A.A.; Sharkey, K.A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Therap. 2010, 126, 21-38.
62. Duncan, M.; Davison, J. S.; Sharkey, K. A. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment. Pharmacol. Ther. 2005, 22, 667-683.
63. Duncan, M.; Thomas, A. D.; Cluny, N. L.; Patel, A.; Patel, K. D.; Lutz, B.; Piomelli, D.; Alexander, S. P.; Sharkey, K. A. Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am. J. Physiol. Gastrointes. Liver Physiol. 2008, 295, G1255-G1265.
64. Bisogno, T.; Berrendero, F.; Ambrosino, G.; Cebeira, M.; Ramos, J. A.; Fernandez-Ruiz, J. J.; Di Marzo, V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 1999, 256, 377-380.
65. Seagard, J.L.; Dean, C.; Patel, S.; Rademacher, D.J.; Hopp, F.A.; Schmeling, W.T.; Hillard, C.J. Anadamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H992-H1000.
66. Darmani, N. A.; Sim-Selley, L. J.; Martin, B. R.; Janoyan, J. J.; Crim, J. L.; Parekh, B.; Breivogel, C. S. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Eur. J. Pharmacol. 2003, 459, 83-95.
67. Herkenham, M.; Lynn, A. B.; Johnson, M. R.; Melvin, L. S.; de Costa, B. R.; Rice, K. C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci 1991, 11, 563-583.
68. Mailleux, P.; Parmentier, M.; Vanderhaeghen, J. J. Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci. Lett. 1992, 143, 200-204.
69. Derbenev, A. V.; Stuart, T. C.; Smith, B. N. Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J. Physiol. 2004, 559, 923-38.
70. Shiroshita, Y.; Koga, T.; Fukuda, H. Capsaicin in the 4th ventricle abolishes retching and transmission of emetic vagal afferents to solitary nucleus neurons. Eur. J. Pharmacol. 1997, 339, 183-192.
71. Burdyga, G.; Lal, S.; Varro, A.; Dimaline, R.; Thompson, D. G.; Dockray, G. J. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J. Neurosci. 2004, 24, 2708-2715.
72. Krowwicki, Z.K.; Moerschbaecher, J.M.; Winsauer, P.J.; Digvalli, S.V.; Hornby, P.J. Delta9- tetrahydrobannabinol inhibits gastric motility in the rat through cannabinoidCB1 receptors. Eur. J. Pharmacol. 1999, 371, 187-196.
73. Anand, U.; Otto, W. R.; Sanchez-Herrera, D.; Facer, P.; Yiangou, Y.; Korchev, Y.; Birch, R.; Benham, C.; Bountra, C.; Chessell, I. P.; Anand, P. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008, 138, 667-680.
74. Andrews, P. L.; Bhandari, P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993, 32, 799-806.
75. Rudd, J. A.; Wai, M. K. Genital grooming and emesis induced by vanilloids in Suncus murinus, the house musk shrew. Eur. J. Pharmacol. 2001, 422, 185-195.
76. Yamakuni, H.; Sawai-Nakayama, H.; Imazumi, K.; Maeda, Y.; Matsuo, M.; Manda, T.; Mutoh, S. Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur. J. Pharmacol. 2002, 442, 273-278.
77. Schicho, R.; Florian, W.; Liebmann, I.; Holzer, P.; Lippe, I.T. Increased expression of TRPV1 receptor in dorsal root ganglia by acid insult of the rat gastric mucosa. Eur. J. Neurosci. 2004, 19, 1811-1818.
78. Szallasi, A.; Blumberg, P. M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev. 1999, 51, 159-212.
79. Landi, M.; Croci, T.; Rinaldi-Carmona, M.; Maffrand, J. P.; Le Fur, G.; Manara, L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur. J. Pharmacol. 2002, 450, 77-83.
80. Darmani, N. A.; Johnson, J. C. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur. J. Pharmacol. 2004, 488, 201-212.
81. Lehmann, A.; Blackshaw, L. A.; Branden, L.; Carlsson, A.; Jensen, J.; Nygren, E.; Smid, S. D. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002, 123, 1129-1134.
82. Duncan, M.; Mouihate, A.; Mackie, K.; Keenan, C. M.; Buckley, N. E.; Davison, J. S.; Patel, K. D.; Pittman, Q. J.; Sharkey, K. A. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G78-G87.
83. Izzo, A. A. The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol. Motil. 2007, 19, 704-708.
84. Storr, M. A.; Keenan, C. M.; Emmerdinger, D.; Zhang, H.; Yuce, B.; Sibaev, A.; Massa, F.; Buckley, N. E.; Lutz, B.; Goke, B.; Brand, S.; Patel, K. D.; Sharkey, K. A. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med. 2008, 86, 925-936.
85. Hillsley, K.; McCaul, C.; Aerssens, J.; Peeters, P. J.; Gijsen, H.; Moechars, D.; Coulie, B.; Grundy, D.; Stead, R. H. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol. Motil. 2007, 19, 769-777.
86. Starowicz, K.; Nigam, S.; Di Marzo, V. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 2007, 114, 13-33.
87. Coutts, A. A.; Izzo, A. A. The gastrointestinal pharmacology of cannabinoids: an update. Curr. Opin. Pharmacol. 2004, 4, 572-579.
88. McVey, D. C.; Schmid, P. C.; Schmid, H. H.; Vigna, S. R. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J. Pharmacol. Exp. Ther. 2003, 304, 713-722.
89. Darmani, N. A. Endocannabinoids and gastrointestinal function. In The Brain and Body's Marijuana and Beyond; Onaivi, E. S., Sugiura, T., Di Marzo, V., Eds.; CRC: Boca Raton, USA, 2005; pp: 393-418.
90. Pinto, L.; Capasso, R.; Di Carlo, G.; Izzo, A. A. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66, 333-341.
91. Darmani, N. A.; McClanahan, B. A.; Trinh, C.; Petrosino, S.; Valenti, M.; Di Marzo, V. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 2005, 49, 502-513.
92. Storr, M. A.; Sharkey, K. A. The endocannabinoid system and gut-brain signaling. Curr. Opin. Pharmacol. 2007, 7, 575-582.
93. Machado Rocha, F. C.; Stefano, S. C.; De Cassia Haiek, R.; Rosa Oliveira, L. M.; Da Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis (Engl). Eur. J. Cancer Care 2008, 17, 431-443.
94. Tramer, M. R.; Carroll, D.; Campbell, F. A.; Reynolds, D. J.; Moore, R. A.; McQuay, H. J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001, 323, 16-21.
95. 9 - THC with classically used antiemetics against the acute phase of cispaltin-induced emesis. Soc. Neurocience Abs. 2006, No. 766.3.
96. Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rossner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365, 1389-1397.
97. Lichtman, A. H.; Wiley, J. L.; LaVecchia, K. L.; Neviaser, S. T.; Arthur, D. B.; Wilson, D. M.; Martin, B. R. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur. J. Pharmacol. 1998, 357, 139-148.
98. Salamone. J.D.; McLaughlin, P.J.; Sink, K.; Makriyannis, A.; Parker, L.A., Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Phys. Behav. 2007, 91, 383-388.
99. McLaughlin, P.J.; Winston, K.M.; Limbeer, C.K.; Parker, L.A.; Makriyamis, A; Salamone, J.D. The cannabinoid CB1 antagonist AM251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 2005, 180, 286-293.
100. Darmani, N. A.; Janoyan, J. J.; Kumar, N.; Crim, J. L. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav. 2003, 75, 777-787.
101. Schlicker, E.; Kathman, M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 2001, 22, 565-572.
102. Darmani, N.A. The cannabinoid CB1 receptor antagonist SR141716A reverses the antiemetic and motor depressant actions of WIN55, 212-2. Eur. J. Pharmacol. 2001, 430, 49-58.
103. Darmani, N.A. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol. Biochem. Behav. 2001, 69, 239-249.
104. London, S.W.; McCarthy, L.E.; Borison, H.L. Suppression of cancer-induced vomiting in the cat by nabilone, a synthetic cannabinoid. Proc. Soc. Exp. Biol. Med. 1979, 160, 437-440.
105. Kwiatkowska, M.; Parker, L. A.; Burton, P.; Mechoulam, R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 2004, 174, 254-259.
106. Ferrari, F.; Ottani, A.; Giuliani, D. Cannabimimetic activity in rats and pigeons of Hu 210, a potent antiemetic drug. Pharmacol. Biochem. Behav. 1999, 62, 75-80.
107. Abrahamov, A.; Abrahamov, A.; Mechoulam, R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995, 56, 2097-102.
108. 9 - THC prevents emesis produced by l-dopa in the least shrew. Soc. Neuroscience Abs. 2006, Number 765.26.
109. Darmani, N. A.; Crim, J. L. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol. Biochem. Behav. 2005, 80, 35-44.
110. Darmani, N. A.; Janoyan, J. J.; Crim, J.; Ramirez, J. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur. J. Pharmacol. 2007, 563, 187-196.
111. th Annual Symposium on the Cannabinoids, Clearwater, FL, USA, 2005.
112. Simoneau, II.; Hamza, M. S.; Mata, H. P.; Siegel, E. M.; Vanderah, T. W.; Porreca, F.; Makriyannis, A.; Malan, T. P., Jr. The cannabinoid agonist WIN55,212-2 suppresses opioidinduced emesis in ferrets. Anesthesiology 2001, 94, 882-887.
113. Cluny, N.L.; Naylor, R.J.; Whittle, B.A.; Javid, F.A. The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin. Pharmacol. Toxicol. 2008, 103, 150-156.114.
114. Hu, D. L.; Zhu, G.; Mori, F.; Omoe, K.; Okada, M.; Wakabayashi, K.; Kaneko, S.; Shinagawa, K.; Nakane, A. Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor. CelL Microbiol. 2007, 9, 2267-2277.
115. du Sert, N. P.; Rudd, J. A.; Moss, R.; Andrews, P. L. R. The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervations in the ferret. Neurosc. Lett. 2009, 465, 16-20.
116. Horn, C. C.; Ciucci, M.; Chaudhury, A. Brain Fos expression during 48 h after cisplatin treatment: neural pathways for acute and delayed visceral sickness. Auton. Neurosci. Basic Clin. 2007, 132, 44-51.
117. Meiri, E.; Jhangiani, H.; Vredenburgh, J. J.; Barbato, L. M.; Carter, F. J.; Yang, H. M.; Baranowski, V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr. Med. Res. Opin. 2007, 23, 533-543.
118. Wang, Y.; Ray, A. P.; McClanahan, B. A.; Darmani, N. A. The antiemetic interaction of Delta9- tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol. Biochem. Behav. 2008, 91, 367-373
119. Fink, K. B.; Gothert, M. 5-HT receptor regulation of neurotransmitter release. Pharmacol. Rev. 2007, 59, 360-417.
120. Barann, M.; Molderings, G.; Bruss, M.; Bonisch, H.; Urban, B. W.; Gothert, M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br. J. Pharmacol. 2002, 137, 589-596.
121. Xiong, W.; Hosoi, M.; Koo, B.; Zhang, L. Anandamide inhibition of 5-HT3A receptors varies with receptor density and desensitization. Mol. Pharmacol. 2007, 73, 314-322.
122. Higa, G. M.; Auber, M. L.; Altaha, R.; Piktel, D.; Kurian, S.; Hobbs, G.; Landreth, K. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J. Oncol. Pharm. Practice 2006, 12, 201-209.
123. Ray, A.P.; Chevolu, S.; Ramirez, J.; Damani, N.A. Ablation of least shrew central NK1 receptors reduces GR73632-induced vomiting. Behav. Neurosci. 2009,123, 701-706.
124. Niranen, A.; Mattson, K. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am. J. Clin. Oncol. 1987, 10, 325-329.
125. Darmani, N.A.; McClanahan, B.A.; Trinh, C.; Petrosino, S; Valenti, M.; Di Marzo, V. Cisplatin increases 2-arachidonoyylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 2005, 49, 502-513.
126. Girod, V.; Dapzol, J.; Bouvier, M.; Grelot, L. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets. Neuropharmacology 2002, 42, 428-436.
127. Wislicki, L. Systemic adverse reactions to prostaglandin F2 (PGF2 alpha, dinoprostone, prostin F2 alpha, prostalmon F). Int. J. Biol. Res. Pregnancy 1982, 3, 158-160.
128. Wechsung, E. The involvement of prostaglandins in the inhibiting effect of endotoxin on the myoelectric activity of the gastrointestinal system in pigs. Verh K. Acad. Geneeskd. Belg. 1996, 58, 711-738.
129. Gadsby, R.; Barnie-Adshead, A.; Grammatoppoulos, D.; Gadsby, P. Nausea and vomiting in pregnancy: an association between symptoms and maternal prostaglandin E2. Gynecol. Obstet. Invest. 2000, 50, 149-152.
130. Jett, M.; Brinkley, W.; Neill, R.; Gemski, P.; Hunt, R. Staphylococcus aureus enterotoxin B challenge of monkeys: correlation of plasma levels of arachidonic acid cascade products with occurrence of illness. Infect. Immun. 1990, 58, 3494-3499.
131. Wang, T.;Collet, J.P.; Shapiro, S.; Ware, M.A. Adverse effects of medical cannabinoids: A systematic review. CMAJ 2008, 178, 1669-1678.
132. Allen, J.H.; de Moore, G.M.; Heddle, R,; Twantz, J.C. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004, 53, 1566-1570.
133. Darmani, N.A. Cannabinoid-induced hyperemesis: A conundrum-from clinical recognition to basic science mechanisms. Pharmaceuticals 2010, 3, 2163-2177.